Dabigatran and Deep Venous Thrombosis

An observational study to assess the efficacy of Dabigatran on recanalisation of veins in newly detected Deep Venous Thrombosis

Status

Recruiting

Phases

Phase 3

Study type

Observational

Source

CTRI

Registry ID

CTRI/2023/05/052825

Enrollment

Registered

2023-05-18

Start date

Unknown

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I824- Acute embolism and thrombosis of deep veins of lower extremity

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with newly diagnosed Deep Vein Thrombosis 2. Patients who have not previously received DVT prophylaxis 3. Patients who are not receiving any anticoagulant or antiplatelet therapy. 4. Age group: >18 years of age. 5. Patients without any known co- morbid conditions predisposing to hypercoagulable state.

Exclusion criteria

Exclusion criteria: 1. Age < 18 years- Patients with ongoing pregnancy. 2. Patients who have received DVT prophylaxis. 3. Previously known case of lower limb DVT 4. Patients on anticoagulant or antiplatelet therapy. 5. Patients with known co-morbid conditions predisposing to hyper-coagulable states

Design outcomes

Primary

Measure	Time frame
The effectiveness of Dabigatran in recanalization of veins as seen in serial venous dopplers ,pre and post initiation of therapy.Timepoint: 6 months	—

Secondary

Measure	Time frame
It is measured as complete resolution of DVT based on venous doppler findings and clinical betterment of the patient in terms of pain, limb girth, color of the limb, features of venous insufficiencyTimepoint: 6 months	—

Countries

India

Contacts

Public ContactDr Jithin Abraham Jacob

Kasturba Medical College , Manipal

jithin.abraham@manipal.edu9632883146

Outcome results